These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38703180)

  • 1. Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan.
    Nakamura S; Mikami M; Hayamizu T; Yonemoto N; Moyon C; Gouldson M; Crossan C; Vietri J; Kamei K
    Expert Rev Vaccines; 2024; 23(1):546-560. PubMed ID: 38703180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan.
    Shinjoh M; Togo K; Hayamizu T; Yonemoto N; Morii J; Perdrizet J; Kamei K
    Expert Rev Vaccines; 2024; 23(1):485-497. PubMed ID: 38682661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
    Rey-Ares L; Averin A; Mac Mullen M; Hariharan D; Atwood M; Carballo C; Huang L
    Infect Dis Ther; 2024 Jun; 13(6):1235-1251. PubMed ID: 38700655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina.
    Rey-Ares L; Ta A; Freigofaite D; Warren S; Mac Mullen M; Carballo C; Huang L
    Vaccine; 2024 Oct; 42(23):126043. PubMed ID: 38879409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England.
    Danelian G; Burton L; Bayley T; Sanchez-Marroquin A; Park J; Manley H; Choi Y; Andrews N; Ladhani S; Earnshaw A; Gritzfeld JF; Trotter C; Panovska-Griffiths J
    Vaccine; 2024 Jul; 42(18):3838-3850. PubMed ID: 38763851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.
    Kang DW; Kim CR; Song JY; Park SK
    Vaccine; 2024 Feb; 42(4):871-878. PubMed ID: 38225184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly.
    Hoshi SL; Shono A; Seposo X; Okubo R; Kondo M
    Vaccine; 2022 Nov; 40(49):7057-7064. PubMed ID: 36273987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis.
    Altawalbeh SM; Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
    Value Health; 2024 Jun; 27(6):721-729. PubMed ID: 38462225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea.
    Kang DW; June Choe Y; Lee JY; Suk IA; Kim YS; Kim HY; Byun BK; Park SK
    Vaccine; 2024 Sep; 42(22):126000. PubMed ID: 38845302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in the cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults.
    Wateska AR; Nowalk MP; Altawalbeh SM; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
    J Am Geriatr Soc; 2024 Aug; 72(8):2423-2433. PubMed ID: 38822745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan.
    Jiang Y; Yang X; Taniguchi K; Petigara T; Abe M
    J Med Econ; 2018 Jul; 21(7):687-697. PubMed ID: 29723081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine.
    Gouveia M; Jesus G; Inês M; Costa J; Borges M
    Hum Vaccin Immunother; 2019; 15(4):850-858. PubMed ID: 30633615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland.
    Owusu-Edusei K; Favre-Bulle A; Tsoumani E; Mutschler T; Cossrow N
    Vaccine; 2024 May; 42(13):3239-3246. PubMed ID: 38609806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population.
    Fridh AC; Palmborg A; Ta A; Freigofaite D; Warren S; Perdrizet J
    Hum Vaccin Immunother; 2024 Dec; 20(1):2400751. PubMed ID: 39279284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.
    Castiglia P; Pradelli L; Castagna S; Freguglia V; Palù G; Esposito S
    Hum Vaccin Immunother; 2017 Oct; 13(10):2307-2315. PubMed ID: 28700264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
    Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
    PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.
    Smith KJ; Wateska AR; Nowalk MP; Raymund M; Nuorti JP; Zimmerman RK
    JAMA; 2012 Feb; 307(8):804-12. PubMed ID: 22357831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru.
    Gomez JA; Tirado JC; Navarro Rojas AA; Castrejon Alba MM; Topachevskyi O
    BMC Public Health; 2013 Oct; 13():1025. PubMed ID: 24171921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults.
    Feldman C; Dlamini SK; Madhi SA; Meiring S; von Gottberg A; de Beer JC; de Necker M; Stander MP
    PLoS One; 2020; 15(1):e0227945. PubMed ID: 31995597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.